Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain

Background Cancer patients often need wide-ranging antimicrobials because of febrile neutropenia, weakened immune systems, frequent hospitalizations, and microbial diversity. Targeted antimicrobial stewardship programs (ASPs) can enhance antimicrobial use while ensuring prompt treatment and maintaining clinical safety. Objectives To assess if the gradual introduction of a precision ASP in cancer treatment led to decreased use of antimicrobials, enhanced microbiology-driven optimization, and positive clinical results. Patients and methods This retrospective, real-world, patient-level study analyzed oncology ASP records from Bahrain Oncology Center–King Hamad University Hospital, covering October–December 2024 (preliminary phase) with January–March 2025 (full implementation). Outcomes included antibiotic duration, antimicrobial phases, DOT per 1,000 patient-days, organism profile, infection source, 14-day readmission, and exploration 30-day survival. Descriptive statistics, phase comparisons, logistic regression, and Cox modelling were performed. Results Out of 1,020 records, median duration of antibiotic use fell from 7 to 0 days. Three-phase courses fell from 63% to 28%, whereas records lacking an antimicrobial phase rose from 11% to 40%. Aggregate recorded DOT decreased from 5,139 during the preliminary phase to 4,923 during full implementation. The fourteen-day readmission rate fell from 27.6% to 17.9% (adjusted OR 0.54, 95% CI 0.34–0.86; p = 0.011). The 30-day survival adjusted was non-significant (HR 1.51, 95% CI 0.94–2.42; p = 0.088). Conclusion Phased implementation of a structured, pharmacist-led and microbiology-informed ASP was associated with more selective antimicrobial use and improved stewardship-process measures in an adult oncology setting. The findings support the feasibility of this model in high-risk cancer care, while prospective multicentre studies with standardized appropriateness and safety outcomes are needed to confirm effectiveness, generalizability, and sustainability.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-11-17
DOI
https://doi.org/10.3389/fpubh.2026.2011882
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain

Nouran Ameen Elsayed Hamza, Abdullahٰ Aljasar, Zainab Aljasar, Manaf Al Qahtani et al.
3 links
Frontiers in Public Health
Antibiotic Use and Resistance
article

Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain

Nouran Ameen Elsayed Hamza, Abdullahٰ Aljasar, Zainab Aljasar, Manaf Al Qahtani, Hager Salaheldin, Yousuf Al-Yousufi, Mooza Al Mannai, Talal Siddiqui, Obada Al-Obaidi, Yasmeen Almafraji
article en

Abstract

Background Cancer patients often need wide-ranging antimicrobials because of febrile neutropenia, weakened immune systems, frequent hospitalizations, and microbial diversity. Targeted antimicrobial stewardship programs (ASPs) can enhance antimicrobial use while ensuring prompt treatment and maintaining clinical safety. Objectives To assess if the gradual introduction of a precision ASP in cancer treatment led to decreased use of antimicrobials, enhanced microbiology-driven optimization, and positive clinical results. Patients and methods This retrospective, real-world, patient-level study analyzed oncology ASP records from Bahrain Oncology Center–King Hamad University Hospital, covering October–December 2024 (preliminary phase) with January–March 2025 (full implementation). Outcomes included antibiotic duration, antimicrobial phases, DOT per 1,000 patient-days, organism profile, infection source, 14-day readmission, and exploration 30-day survival. Descriptive statistics, phase comparisons, logistic regression, and Cox modelling were performed. Results Out of 1,020 records, median duration of antibiotic use fell from 7 to 0 days. Three-phase courses fell from 63% to 28%, whereas records lacking an antimicrobial phase rose from 11% to 40%. Aggregate recorded DOT decreased from 5,139 during the preliminary phase to 4,923 during full implementation. The fourteen-day readmission rate fell from 27.6% to 17.9% (adjusted OR 0.54, 95% CI 0.34–0.86; p = 0.011). The 30-day survival adjusted was non-significant (HR 1.51, 95% CI 0.94–2.42; p = 0.088). Conclusion Phased implementation of a structured, pharmacist-led and microbiology-informed ASP was associated with more selective antimicrobial use and improved stewardship-process measures in an adult oncology setting. The findings support the feasibility of this model in high-risk cancer care, while prospective multicentre studies with standardized appropriateness and safety outcomes are needed to confirm effectiveness, generalizability, and sustainability.

Frontiers in Public HealthVol. 14
Royal College of Surgeons in Ireland - Bahrain (BH), Saudi Center for Disease Prevention and Control (SA), King Hamad University Hospital (BH)
Good health and well-being
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon